KAKINETA, INC./DE

Nasdaq yumanity.com


$ 0.46 $ -0.03 (-5.54 %)    

Friday, 17-May-2024 15:55:42 EDT
QQQ $ 451.63 $ -1.09 (-0.24 %)
DIA $ 399.76 $ 0.64 (0.16 %)
SPY $ 529.24 $ 0.31 (0.06 %)
TLT $ 91.40 $ -0.22 (-0.24 %)
GLD $ 223.63 $ 1.39 (0.63 %)
$ 0.487
$ 0.47
$ 0.00 x 0
$ 0.00 x 0
$ 0.46 - $ 0.48
$ 0.33 - $ 5.39
53,742
na
5.57M
$ -0.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-10-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 03-08-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-14-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-30-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kineta-provides-update-on-its-ongoing-phase-12-vista-101-clinical-trial-and-corporate-activities-received-500000-investment-from-an-existing-investor

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts ...

 kineta-q1-eps-089-misses-021-estimate

Kineta (NASDAQ:KA) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.21) by 323...

 kineta-granted-us-patent-titled-proteasome-activity-enhancing-compounds-including-methods-for-treating-cancer-or-tumors

https://ppubs.uspto.gov/dirsearch-public/image-conversion/convert?url=uspat/US/G73/588/119/00000001.tif&requestToken=eyJzdW...

 why-medical-properties-trust-shares-are-trading-higher-by-around-13-here-are-20-stocks-moving-premarket

Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced th...

 why-ascent-solar-technologies-shares-are-trading-lower-by-around-50-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced p...

 why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

 kineta-reports-initial-clinical-response-data-at-aacr-2024-of-ongoing-phase-12-vista-101-clinical-trial

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts ...

 kineta-fy-2023-gaap-eps-128-beats-140-estimate-sales-5442m-miss-5592m-estimate

Kineta (NASDAQ:KA) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.40) by 8.57 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION